ArticleFrontiers in oncology2025

Retrospective analysis of the efficacy and safety of anlotinib plus sintilimab (anti-PD-1) as maintenance therapy in advanced pediatric solid tumors.

Rui Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.